Kimberly Wynne
Family Medicine · Dublin, GANPI 1811613797
Payments from drug & device makers
Across 97 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$246
- Novartis$212
- Merck$189
- Bristol Myers Squibb$118
- Amgen$95
- Karyopharm Therapeutics Inc.$90
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,02595%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $246 |
| Novartis | 10 | $212 |
| Merck | 8 | $189 |
| Bristol Myers Squibb | 5 | $118 |
| Amgen | 5 | $95 |
| Karyopharm Therapeutics Inc. | 4 | $90 |
| Regeneron Healthcare Solutions, Inc. | 4 | $79 |
| Astellas Pharma US Inc | 4 | $75 |
| Seagen Inc. | 3 | $74 |
| Pfizer | 4 | $69 |
| Pharmacosmos Therapeutics Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Genentech USA, Inc. | 2 | $56 |
| Johnson & Johnson(2 entities) | 3 | $55 |
| Boehringer Ingelheim | 2 | $50 |
| Sanofi | 2 | $49 |
| Lilly USA, LLC | 2 | $43 |
| Boston Scientific | 2 | $39 |
| Mirati Therapeutics, Inc. | 2 | $39 |
| Beigene USA, Inc. | 2 | $38 |
| G1 Therapeutics, Inc. | 2 | $32 |
| Myriad Genetic Laboratories, Inc. | 1 | $32 |
| GSK | 2 | $28 |
| Exelixis Inc. | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Incyte Corporation | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Immunogen, Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Morphosys, US Inc. | 1 | $14 |
How this compares
$2,125 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 13 | $78 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Dublin
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.